![](https://investorshub.advfn.com/uicon/507416.png?cb=1538015923)
Sunday, April 10, 2022 7:28:55 AM
123414 Still long TLTFF.
The 67% CR@ 18/24 months is unmatched.
Those full dose patients are becoming dominate in the study.
Under-treaded patients are still in the mix but getting reduced.
AND... Now the kicker... the undertreated patients were not treated in the protocol of the study.
Read what the analysis says about all the one dose patients.
TLTFF on track and still solid as heck.
That's why that analyists moved his rating to .95usd / 1.20cad
He nailed it before.
Stay tuned sports fan the race is just heating up.
Theralase Technologies receives a target raise from Research-Capital
https://www.cantechletter.com/2022/04/theralase-technologies-receives-a-target-raise-from-research-capital/
JMO, maybe, maybe not.
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM